Allergan's most recent trend suggests a bearish bias. One trading opportunity on Allergan is a Bear Call Spread using a strike $245.00 short call and a strike $250.00 long call offers a potential 18.76% return on risk over the next 4 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $245.00 by expiration. The full premium credit of $0.79 would be kept by the premium seller. The risk of $4.21 would be incurred if the stock rose above the $250.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Allergan is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Allergan is bearish.
The RSI indicator is at 29.44 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Allergan
Allergan, Schlumberger, Caterpillar: Doug Kass' Views
Mon, 13 Mar 2017 05:00:00 GMT
Trump nominates FDA head with deep ties to drug companies
Fri, 10 Mar 2017 22:57:57 GMT
Reuters – U.S. President Donald Trump has chosen Dr. Scott Gottlieb, a conservative health policy expert with deep ties to the pharmaceutical industry, to lead the U.S. Food and Drug Administration, a White House official said on Friday. If confirmed by the Senate, Gottlieb would be in charge of implementing Trump's plan to dramatically cut regulations governing food, drugs, cosmetics, dietary supplements and tobacco.
Allergan plc Question if a Feminist Can Love Fillers?
Thu, 09 Mar 2017 19:00:00 GMT
PR Newswire – Allergan plc (AGN), a leading global pharmaceutical company and maker of Juvéderm® facial fillers, reveals the outcome of a heated debate tackling the view that women who enhance the way they look, can be seen as frivolous, or even anti-feminist. The debate, hosted by Cosmetic Executive Women and supported by Allergan, explored new research into women's attitudes towards the quest for beauty and youth. The panellists were Polly Vernon (author of Hot Feminist), Bryony Gordon (author of Mad Girl), journalist Sarah Vine and leading Aesthetic Practitioner, Alison Telfer.
Allergan's (AGN) Vraylar sNDA Accepted for Review by FDA
Thu, 09 Mar 2017 15:55:03 GMT
David Tepper Discusses Allergan Investment, Market Valuation
Wed, 08 Mar 2017 21:08:29 GMT
Also on Market Tamer…
Follow Us on Facebook